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7Highly pathogenic adapted HIV-1 strains limit host
immunity and dictate rapid disease progression
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ISObjective: The study of HIV-1 rapid progressors has been limited to specific case
reports. Nevertheless, identification and characterization of the viral and host factors
involved in rapid progression are crucial when attempting to uncover the correlates of
rapid disease outcome.
Design: Wecarriedout comparative functional analyses in rapidprogressors (n¼46) and
standard progressors (n¼46) early after HIV-1 seroconversion (1 year). The viral traits
tested were viral replicative capacity, co-receptor usage, and genomic variation. Host
CD8þ T-cell responses, humoral activity, and HLA immunogenetic markers were also
determined.
Results: Our data demonstrate an unusual convergence of highly pathogenic HIV-1
strains in rapid progressors. Compared with standard progressors, rapid progressor
viral strains show higher in-vitro replicative capacity (81.5 vs. 67.9%; P¼0.025) and
greater X4/DM co-receptor usage (26.3 vs. 2.8%; P¼0.006) in early infection.
Limited or absent functional HIV-1 CD8þ T-cell responses and neutralizing activity
were measured in rapid progressors. Moreover, the increase in common HLA
allele-restricted CD8þ T-cell escape mutations in rapid progressors acts as a signature
of uncontrolled HIV-1 replication and early impairment of adaptive cellular
responses.
Conclusion: Our data support a dominant role for viral factors in rapid progressors.
Robust HIV-1 replication and intrinsic viral properties limit host adaptive immune
responses, thus driving rapid disease progression.
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The clinical outcome of HIV-1-infected patients varies
considerably. In the absence of antiretroviral therapy, the
median time to development of AIDS has been estimated
to vary from 7.7 to 11.0 years, depending on age at sero-
conversion [1]. Nevertheless, some individuals are able to
control HIV-1 replication for longer periods (HIV-1 con-
trollers and elite controllers), whereas others progress
quickly to AIDS or meet the criteria for initiation of
antiretroviral treatment within the first 3 years after sero-
conversion (rapid progressors). Thus, research into
extreme phenotypes can provide us with invaluable data
on the contribution of viral and host factors to HIV-1
disease outcome [2–4].
Most studies on extreme HIV-1 phenotypes have focused
on HIV-1 controllers and elite controllers as models for
defining the correlates of protective immunity and control
of viral replication [3,5]. The study of rapid progressors, on
the contrary, has proved particularly challenging, because
identification of this phenotype requires a reliable estima-
tion of the seroconversion date within a small observation
window [4]. This limitation is even more remarkable if we
consider that multiple biological samples need to be taken
for analysis. Consequently, very few core studies have
analysed rapid progressors, and the data reported thus far
are heterogeneous [6–8]. Nevertheless, the factors contri-
buting to rapid disease progression must be uncovered to
improve the clinical management of these individuals.
The present study is based on a previous case report study
analysing extremely severe progression of HIV-1 infection
[7] and attempts to broadly characterize rapidprogressors in
functional terms by assessing viral and host factors. Our
objective was to provide new insights into the causes of
rapid disease progression.We recruited anunprecedentedly
large group of rapid progressors and systematically com-
pared them toHIV-1-infected patientswith average disease
progression. Our selection criteria for rapid progressors
were based on the reduction in CD4þ T-cell counts to less
than 350 cells/ml within 3 years after documented
seroconversion in the absence of antiretroviral treatment,
as previously validated by our genomic studies [4].
Our findings reveal a profile of HIV-1-specific traits (e.g.
replicative capacity, co-receptor usage, and virus varia-
bility) that is common to rapid progressors. Additional
differences between groups were observed in cellular and
humoral immune profiles and in HLA class I immuno-
genetics.Material and methods
Cohort description and study groups
We established two progression cohorts: one from
IrsiCaixa (Barcelona, Spain) and one from the Swisspyright © Lippincott Williams & Wilkins. UnauthoHIV Cohort (Lausanne, Switzerland). The cohorts were
defined based on anHIV-1 seroconversion windowof less
than 1 year and documented negative and positive
serology result. Disease progression stage was established
during the 3 years after seroconversion (Fig S1, http://
links.lww.com/QAD/A517). Patients in the first cohort
(CoRP, n¼ 106) had two or more CD4þ T-cell counts
below 350 cells/ml with no subsequent increase in the
absence of antiretroviral treatment. Individuals with
average progression or standard progressors (CoSP,
n¼ 84) maintained CD4þ T-cell counts above
350 cells/ml over the same period in the absence of
antiretroviral treatment. From these two cohorts, we
selected two study groups: the rapid progressors (n¼ 46)
and the standard progressors (n¼ 46). These groups were
selected based on clinical data and sample availability early
after HIV-1 seroconversion at baseline (median 1 year)
and a median of 1.5 years from initial sampling post-
baseline. Samples were distributed and prioritized
according to functional analysis (for details, see Fig S1,
http://links.lww.com/QAD/A517). The characteristics
of both groups are summarized in Table 1. Differences in
themode of HIV-1 transmission between the groups were
due to an increase in the number of intravenous drug users
(IVDUs) in rapid progressors. Consistency of the results
was demonstrated by sensitivity analyses in all data sets
regardless of the presence of IVDUs in rapid progressors.
The project was approved by the institutional review
boards of Hospital Germans Trias i Pujol and the
University Hospital of Lausanne. Participants gave their
written informed consent to participate.
HIV-1 isolation, replicative capacity, and
co-receptor usage
Viral isolates were obtained from plasma samples using
anti-CD44 beads (Miltenyi Biotec, Germany [7,9]. Viral
isolates from cryopreserved PBMCs were obtained by
co-culture as described in reference [7]. Virus replicative
capacity was determined for all isolates. Viral growth was
monitored by p24 ELISA in supernatants (Perkin Elmer,
Spain), and replicative capacity was calculated by the slope
of p24 production in the exponential growth phase [10].
Tropism from viral isolates was measured in U87-
immortalized cell lines expressing CCR5 or CXCR4
[11]. Virus tropism was assessed in parallel in plasma
samples using the enhanced sensitivity tropism assay
(ESTA).
HLA typing and assessment of HIV-1-specific
CD8R T-cell responses
High-resolution HLA class I typing for alleles A, B, and
Cw was performed by sequence-based typing methods.
Comprehensive HIV-1 epitope screening of optimal
responses was carried out using the interferon-g (IFN-g)
ELISpot assay in a subset of patients, as previously
described [12] (Table S1, http://links.lww.com/QAD/
A517).Wells were considered positive if they contained at
least 50 spot-forming cells per 106 PBMCs above therized reproduction of this article is prohibited.
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Table 1. Characteristics of the rapid and standard progressors included in the study.
Male sex [n (%)] 35 (76.1) 43 (93.5) 0.02
Age at diagnosis of HIV-1 infection, median (IQR) (years) 31 (26–37) 30 (26–35) 0.48
White ethnicity [n (%)] 39 (84.8) 32 (71.1) 0.08
Mode of transmission [n (%)] 0.002
Heterosexual 12 (26.1) 5 (10.9)
MSMa 20 (43.5) 37 (80.4)
IVDUb 10 (21.7) 1 (2.2)
Other and NA 4 (8.7) 3 (6.5)
Viral subtype B [n (%)] 38 (86.4) 43 (93.5) 0.11
Baseline CD4þ T-cell countc [median (IQR)] 385 (245–508) 658 (442–804) <0.0001
Baseline viral loadd [log10 copies/ml, median (IQR)] 4.88 (4.48–5.51) 4.35 (3.75–4.99) 0.02
Viral load set pointe [log10 copies/ml, median (IQR)] 4.73 (4.28–5.21) 4.10 (3.22–4.37) <0.0001
Mean CD4þ T-cell count in the absence of ARTf (IQR) 317.3 (216.1–393.7) 615.3 (518.8–713.6) <0.0001
IQR, inter-quartile range; IVDU, intravenous drug user; NA, not available.
aMSM.
bIntravenous drug users.
cBaseline CD4þ T-cell count was available for 37 rapid progressors and 30 standard progressors.
dBaseline viral load was available for 34 rapid progressors and 28 standard progressors.
eViral load set point was defined by the level of circulating virus in plasma during the non-symptomatic phase preceding progression to AIDS
(steady stage). Data were available for 35 rapid progressors and 37 standard progressors.
fMean CD4þ T-cell count was defined by the mean of the levels of CD4þ cell counts during the non-symptomatic phase preceding progression to
AIDS (steady stage). Data were available for 43 rapid progressors and 39 standard progressors.background level (2 mean þ 3 STD). The frequency
of HIV-1-specific responses was calculated as follows:
[number of positive responses/number of optimal
peptides tested]  100. The frequency of response was
corrected by the number of optimal peptides tested per
sample.
Evaluation of viral susceptibility to neutralization
and plasma HIV-1-neutralizing activity
Neutralization experiments were performed using the
PhenoSense HIV-1 neutralization assay. To determine
virus sensitivity to neutralization in rapid progressors and
standard progressors, Env-pseudotyped viruses from both
groups were tested against a panel of broadly neutralizing
antibodies (bNAbs) (b12, 4E10, 2F5, 2G12). Neutral-
ization values are expressed as the concentration of IgG
that reduces infectivity by 50% (IC50). Heterologous
neutralizing activity of plasma was tested against a
standard panel of HIV-1 isolates. The reference panel
viruses NL4-3, SF162, and JR-CSF were included
as positive controls and aMLV was used as specificity
control. Neutralizing activity was also tested in a panel
of autologous and heterologous Env-pseudotyped
recombinant viruses obtained from plasma samples
[13]. Neutralizing antibody titres in plasma samples were
calculated as described in reference [14].
HIV-1 sequencing and variation at optimal CD8R
T-cell epitopes
Partial HIV-1 genome sequencing was carried out for
Gag and Pol genes in plasma samples from 40 patients
(22 rapid progressors and 18 standard progressors). Gag
and Pol genes were amplified from viral RNA byone-step
RT-PCR and nested PCR. Virus subtype was assigned
using the REGA HIV-1 subtyping tool in Gag and Pol
sequences. Deep sequencing of Gag covering the TW10
region in RP52 was carried out in total viral RNA fromCopyright © Lippincott Williams & Wilkins. Unautplasma or primary viral isolates, as previously described
[7].
Optimal HIV-1 CD8þ T-cell epitopes were tested based
on the best-defined CD8þ epitope summary from the
Los Alamos Molecular Immunology Database. HIV-1
variation at the optimal CD8þ T-cell epitopes was
determined in Gag and Pol viral sequences matched to
patients’ HLA class I alleles with four-digit resolution.
HIV-1 variation at optimal epitopes was defined using the
EPIMAP tool (available upon request), which allowed
fuzzy matching with up to three substitutions per HIV-
1HXB2 epitope and the HLA-I restriction element. The
frequency of virus variation was defined as the ratio of
total mismatches found at optimal epitopes to the number
of total optimal epitopes found per sequence.
Statistical analysis
For the clinical group comparison, P-values were
calculated using the Mann–Whitney and Fisher’s exact
test. The relationship between CD4þ T-cell count and
replicative capacity was assessed using the Spearman’s
correlation coefficient. The statistical significance of the
HLA class allelic distribution was reported after correct-
ing for multiple comparisons using the Benjamin and
Hochberg procedure. All analyses were performed using
SAS 9.3.Results
HIV-1 strains from rapid progressors are highly
replicative and have greater X4/DM co-receptor
usage
Virus replicative capacity and co-receptor usage are
essential for establishing a productive HIV-1 infectionhorized reproduction of this article is prohibited.
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4 AIDS 2014, Vol 00 No 00when transmission bottlenecks occur and for determining
the speed of CD4þ T-cell depletion during early stages.
These viral traits have been widely associated with the
pathogenesis and outcome of HIV-1 infection [15–18]
and are crucial for evaluation in the context of rapid
progression of HIV-1. Thus, we assessed viral replicative
capacity and co-receptor usage in rapid progressors and
compared them with those of standard progressors
in samples obtained early after seroconversion (median
1 year).
We measured replicative capacity in vitro in primary
isolates from rapid progressors (n¼ 27) and standardpyright © Lippincott Williams & Wilkins. Unautho
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Fig. 1. HIV-1 co-receptor usage and replicative capacity in rapi
capacity from primary isolates in rapid progressors (RPs) and stand
27 RP and 20 SP at baseline. Experiments were carried out in stimula
were then infected in duplicate to a multiplicity of infection of 0.00
Variation between replicates was low. Viral growth was measured e
was calculated as the slope in the exponential growth phase for each
100%. The horizontal line represents median values (the P-value w
between baseline CD4þ T-cell counts and replicative capacity. Line
20 SP. The Spearman correlation coefficient (r) and the associa
frequency of R5 and X4/DM virus in RP and SP. Viral tropism was
concordancewas 96%. Discordant results were recorded in only thr
We assigned 2 as R5 by ESTA owing to the very low levels of p24 i
U87-X4 positivity and clonal sequences reporting X4/DM usage. G
(d) Viral load set point stratified by virus co-receptor usage. The
percentiles in 33 RP and 30 SP. The P-values were calculated using
are shown. ESTA, enhanced sensitivity tropism assay.progressors (n¼ 20). Our results revealed a significantly
higher viral replicative capacity in isolates from rapid
progressors than in those from standard progressors in
early infection (median 81.5 vs. 67.9%; P¼ 0.025;
Fig. 1a). We then studied the correlation between
replicative capacity and clinical parameters as predictors of
rapid progression. Our data demonstrate an inverse
correlation between replicative capacity and baseline
CD4þ T-cell counts in the overall study group [19,20]. In
addition, a complementary analysis by disease status
revealed the specific contribution of the highest
replicative virus to the significant association between
replicative capacity and baseline CD4þ T-cell countrized reproduction of this article is prohibited.
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P¼ 0.002).
We also analysed virus co-receptor usage in 74 samples
(38 rapid progressors and 36 standard progressors) using
the ESTA and the U87 phenotypic assay; inter-assay
concordance was 96%.We found a previously unreported
increase in X4/DM co-receptor usage in association with
rapid progression (26.3% rapid progressors vs. 2.8%
standard progressors; P¼ 0.006) (Fig. 1c). These results
indicate the contribution of X4/DM virus to the superior
replicative capacity in a subset of rapid progressors.
However, despite the increase in X4/DM distribution,
the remaining 73.7% of rapid progressors carried R5
variants. These R5 variants were associated with higher
plasma viraemia (P< 0.001; Fig. 1d), thus supporting
the pathogenic properties of the R5 virus in rapid
progressors.
Taken together, these results demonstrate the con-
tribution of virus replicative capacity and X4/DM
co-receptor usage to CD4þ T-cell depletion and rapid
disease progression.
Rapid progressors have weak or absent
anti-HIV-1 cellular and humoral adaptive
responses
Once the viral traits that prevail in HIV-1 rapid
progressors were established, we investigated the contri-
bution of host immune factors to rapid disease outcome.
Therefore, we extended our comparative analyses to
cellular and humoral functional markers in our study
groups. We focused on virus-specific CD8þ T-cell
responses, virus susceptibility to neutralization, and
plasma-neutralizing activity as key components of the
initial adaptive immune responses against HIV-1.
We measured HIV-1-specific CD8þ T-cell responses in
a subgroup of 17 rapid progressors and 13 standard
progressors in a comprehensive panel of optimally
defined HIV-1 CD8þ T-cell epitopes. Our results
demonstrated weak or even absent HIV-1-specific
CD8þ T-cell responses in rapid progressors when
compared to standard progressors at baseline (mean
2.58% rapid progressors vs. 10.45% standard progressors;
P¼ 0.004) (Fig. 2a). These differences in early infection
were maintained when responses were tested later in
infection (post-baseline: mean 1.34% rapid progressors
vs. 8.29% standard progressors; P¼ 0.005) (Fig. 2a), with
no improvement or recovery despite normalization of
CD4þ T-cell levels after initiation of treatment in
rapid progressors.
We also evaluated humoral responses by measuring virus
susceptibility to neutralization and plasma-neutralizing
activities across groups. No differences between rapid
progressors and standard progressors were observed
regarding the sensitivity of HIV-1 Env-pseudotypedCopyright © Lippincott Williams & Wilkins. Unautvirus against a panel of bNAbs (Fig. 2b). Moreover,
plasma-neutralizing activity in 12 rapid progressors and
32 standard progressors was evaluated against a panel of
viral isolates with a wide range of susceptibilities to
neutralization (Table S2, http://links.lww.com/QAD/
A517). Even though a consistent trend towards lower IC50
values was observed in rapid progressors, the results did not
reach statistical significance (Fig. 2c). Similarly, no
differences were found between groups in total heter-
ologous plasma-neutralizing activity (Fig. 2d and Table S3,
http://links.lww.com/QAD/A517). Furthermore, auto-
logous plasma neutralization was generally low against
contemporaneous virus and only increased in standard
progressors over time (rapid progressors vs. standard
progressors; P¼ 0.019) (Fig. 2e). By contrast, autologous
neutralizing titres against ancestral viruses were higher
in both groups [rapid progressors (P¼ 0.024) and
standard progressors (P< 0.0001)], but with a lower
increase in the rapid progressors within the same period
(Fig. 2e).
These data demonstrate the lack of early anti-HIV-1
adaptive host immune response in rapid disease pro-
gression. Weak or absent specific CD8þ T-cell responses,
together with limited neutralizing activity, define a
common dysfunctional immune phenotype in rapid pro-
gressors.
Presence of HIV-1 variants adapted to common
HLA class I alleles is associated with rapid
disease progression
The high rate of initial virus adaptation to or escape from
HLA class I molecules is a major limitation for the early
control of HIV-1 by CD8þ T-cell responses [21]. Thus,
transmission of HLA-adapted variants has been associated
with rapid progression [2], even in individuals with
protective HLA alleles [22,23]. Therefore, in order to
understand the lack of early anti-HIV-1 CD8þ T-cell
responses in rapid progressors, it is critical to identify the
contribution of HIV-1 adaptation to or escape from HLA
class I immunogenetics.
Initially, to define the contribution of HLA-adapted
strains to rapid progression, we focused on patients with
protective HLA class I alleles (HLA-B58 and B27) and
rapid progression. We identified one HLA-B27 rapid
progressors and three HLA-B58 rapid progressors. We
evaluated the existence of adapted virus to protective
KK10 and TW10 Gag epitopes. As a result, we found
immune escape variants at positions K264R in KK10 and
T242N in TW10 in all rapid progressors. By contrast, no
immune escape was observed in two HLA-B27 standard
progressors within the same period of infection (Fig. 3a).
Additionally, Gag K264R and T242N mutations known
to cause viral replication defects [24,25] appeared
alongside compensatory changes in replication at
positions S173 for K264R and I223/G248 for T242N
in rapid progressors (Fig. 3a). Development of such ahorized reproduction of this article is prohibited.
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Fig. 2. HIV-1-specific CD8R T-cell responses, virus sensitivity to neutralization and plasma-neutralizing activity in rapid
progressors and standard progressors. (a) Frequency of IFN-g HIV-1-specific CD8þ T-cell responses at baseline (BL) and post-
baseline (P) were measured in PBMCs against a panel of optimally defined HLA class I HIV-1 epitopes in 17 rapid progressors (RPs)
and 13 standard progressors (SPs). The box and whiskers plot shows median values and 10th and 90th percentiles. The P-values
were calculated using the Mann–Whitney test. Only significant P-values (P<0.05) are shown. (b) Sensitivity to neutralization of
Env-pseudotyped virus derived from the plasma of 24 RP and 31 SP against a panel of broadly neutralizing antibodies (bNAbs)
including b12, 4E10, 2F5, and 2G12. (c) Heterologous plasma-neutralizing activity at baseline against a standard panel of viral
isolates from various subtypes and with various ranges of susceptibilities to neutralization (sensitive, moderate, and resistant).
(d) Heterologous cross-reactive virus-neutralizing activity in plasma samples, at baseline (BLp) and post-baseline (Pp), against a
panel of baseline patient-derived Env-pseudotyped viruses (BLv). (e) Autologous neutralizing activity in plasma and Env-
pseudotyped virus pairs. All P-values were calculated using the Mann–Whitney test. Only significant P-values (P<0.05) are
represented. BLp, baseline plasma; BLv, baseline virus; Pp, post-baseline plasma; Pv, post-baseline virus.
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viral sequences. Red triangles and diamonds are clonal viral sequences obtained from primary viral isolates from cells (RP52vc) or
plasma (RP52vp). Red squares are clonal viral sequences obtained directly from total plasma (RP52p). The alignment next to the
tree shows the clonal populations of TW10 escape variants in RP52. The frequency of the variant in the total population is
expressed as a percentage next to each clonal sequence. RP, rapid progressors; SP, standard progressors.
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[23,26,27] and likely represents a marker of HIV-1
transmission events. This observation is reinforced by the
presence of KK10 escape mutants in non-B27 rapid
progressors (Fig. 3a) and by the homogeneous clonal
populations of TW10 escape mutants found in an HLA-
B58 rapid progressors (Fig. 3b). Overall, these findings
are consistent with the low level of viral genetic variability
described in recent infection and probably identify
transmission events in rapid progression.
With the aim of generalizing previous observations to
specific immunogenetic profiles in rapid progressors, we
performed an exploratory analysis of HLA class I
distribution in 122 HIV-1-infected individuals (74 rapid
progressors and 48 standard progressors). Our data
demonstrate an increase in the frequency of common
Caucasian HLA haplotypes, including HLA-A02:01,
B07:02, and B08:01 in rapid progressors (75.6% rapid
progressors vs. 50% standard progressors) to the detriment
of protective ones (6.76% rapid progressors vs. 22.9%
standard progressors) Fig. 4a. In addition, a modest
increase was observed in risk alleles. Similar trends across
data analyses were supported by individual HLA type
analyses (Table S4, http://links.lww.com/QAD/A517).
In order to evaluate the contribution of virus adaptation
or escape to the immunogenetics of rapid progressors, we
focused on HLA-A02:01 carriers because of their higher
prevalence in the study population. Thus, we determined
HIV-1 variation at the immunodominant A02:01-
restricted SL9-Gag epitope. We compared HIV-1 SL9-
Gag variation in HLA-A02:01-positive individuals
(A02 : 02þve) early after seroconversion (Fig. 4b).
Our data demonstrated preferential variation at position
3 (Y3F), but not position 8, of the SL9-Gag epitope in
A02:01þve rapid progressors when compared to
A02:01þve standard progressors (62.5% rapid progres-
sors vs. 0% standard progressors; P¼ 0.031) (Fig. 4b).
These differences revealed a specific increase in SL9
escape variants in rapid progressors. Furthermore, to
extend these findings to complete viral proteins, we
measured total variation in Gag and Pol regions and
limited the analyses to those epitopes recognized by each
patient’s HLA. Our data indicated a significant increase in
total Gag epitope variation in viral strains from rapid
progressors when compared to standard progressors (1
rapid progressors vs. 0.63 standard progressors; P¼ 0.008)
(Fig. 4c), but not in Pol. Moreover, these differences in
epitope variation were not equally distributed across
functional domains in Gag, but significantly accumulated
in the p24 region (0.87 rapid progressors vs. 0.35 standard
progressors; P¼ 0.0084) (Fig. 4d). These results support
the association between HLA class I adaptation or escape
of HIV-1 variants and rapid disease progression. This
association is marked by a high prevalence of common
Caucasian haplotypes and higher mutational changes
against p24 epitopes.pyright © Lippincott Williams & Wilkins. UnauthoDiscussion
The time required for the development of AIDS after
HIV-1 infection is associated with the temporal equi-
librium between viral and host factors. This dynamic
interplay can be disrupted and present as extreme disease
that either contributes to prolonged periods of HIV-1
control or drives rapid disease progression. In this context,
rapid progression remains one of the least understood
extreme HIV-1 phenotypes, yet it must be understood if
we are to tackle the epidemic. Consequently, the present
study overcomes previous study limitations through the
identification and functional characterization of the
largest group of rapid progressors to date. For the first
time, we provide evidence of the contribution of intrinsic
viral properties to rapid disease progression in a study
group.
Our data demonstrate how viral factors, including robust
HIV-1 replication, higher X4/DM co-receptor usage,
and an increased number of common HLA footprints,
could lead to uncontrolled virus replication. Such a robust
replicative profile will likely limit the generation of
adaptive responses and precipitate rapid disease pro-
gression. The pathogenic HIV-1 strains found in rapid
progressors are rare at the onset of infection, and
discrepancies in viral factors are most apparent with regard
to viral tropism. Thus, the reported prevalence of X4/
DM virus ranged from 5 to 10% in primary infection
[17,28], compared with above 25% in rapid progressors.
However, differences in the selection criteria according to
rapid disease progression might partially account for the
divergence between studies. Although X4/DM viruses
are more pathogenic than R5 viruses [29], R5 variants in
rapid progressors were equally associated with high
replicative capacity and viral load set point. Therefore,
these data highlight a previously unnoticed contribution
of R5 strains to disease progression.
Intrinsic viral properties may also contribute to the
limited adaptive immunity found in rapid progressors,
which is key to controlling HIV-1 replication upon
transmission. We observed defective HIV-1-specific
CD8þ cellular responses and nomajor role of neutralizing
antibodies, as previously reported [30,31]. However, the
generalized static immune phenotype in rapid progressors
does not reflect a pre-existing immunodeficiency [2], but
rather an outstanding loss of CD4þ T cells in primary
infection. The dramatic loss of CD4þ T cells will
irreversibly affect CD4þ homeostasis and thus compro-
mise CD4þ T-cell helper responses and CD8þ T-cell [32]
and B-cell function [33,34]. In addition, subsequent
limited anti-HIV-1-adaptive immunity established early
on could add to the lack of control of viral replication and
disease progression.
In this study, we observed early disruption of host
immunity in favour of viral replication. This phenomenonrized reproduction of this article is prohibited.
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Fig. 4. HLA class I immunogenetics and HIV-1 variation at HLA-matched epitopes in rapid progressors and standard
progressors. (a) Phenotypic frequency (number of patients with a defined haplotype/number of total individuals in the group
 100) in pooled analyses for HLA class I alleles. Patients in groups (74 RP and 48 SP) were included if they had at least one
common allele (A02:01, B07:02 and B08:01), a protective allele (B57:01, B14:01 and B27:05), or a risk allele (B35:02,
B35:03, B35:04 and B53:01). Only those alleles with a frequency above 3% in the overall population were taken into account
for data representation. (b) HIV-1 SL9 epitope alignment in HLA-A02:01þve RP and SP; P3 and P8 indicate amino acid sites in
SL9. The bar graph shows the frequency of epitope variation at P3 and P8 sites in HLA-A02:01þve SP and RP. (c) Frequency of
epitope variation inHIV-1Gag. Partial sequencingwas carried out in a total of 40 patients (22 RP and 18 SP). (d) Frequency of HLA-
matched epitope variation inHIV-1Gag per functional domains p17 and p24. Values in (c) and (d) are expressed asmean and SEM.
The P-values were calculated using the Mann–Whitney test. Only significant P-values (P<0.05) are represented. RP, rapid
progressors; SP, standard progressors.seems to be associatedwith the increase inHLA class I virus
adaptation or escape. HIV-1 adapts to the most frequent
alleles in a population [21]. Therefore, the probability of
transmission of adapted viruses will increase amongCopyright © Lippincott Williams & Wilkins. Unautcommon HLA carriers, thus reducing the chances for a
potent anti-HIV-1 CD8þ T-cell response [21,35].
Consistent with this hypothesis, our data identified the
accumulation of common Caucasian alleles, includinghorized reproduction of this article is prohibited.
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rapid progressors. Our results confirm and extend those of
previous studies showing a disadvantage of A2 and B7
supertypes in control of HIV-1 infection [35,36].
According to this immunogenetics profile, the likelihood
of having adapted or escaped variants should increase in
rapid progression of HIV-1. This observation is consistent
with the presence of well adapted and well compensated
viruses in HLA-B58 and HLA-B27 patients and
reinforced by the spread of SL9 escaped variants in
HLA-A02:01-positive rapid progressors. In addition, the
overall increase in HIV-1 Gag-p24 mutations matched to
HLA class I epitopes in rapid progressors, but not in
standard progressors, points to the existence of adapted or
escape variants during the first year after seroconversion.
Despite the fact that we cannot directly associate specific
amino acid changes in Gag-p24 epitopes with HIV-1
escape, multiple intra-epitope variation might interfere
with the generation of particularly protective Gag CD8þ
T-cell responses [3,37–39]. Although our study demon-
strated an increase in HLA class I-adapted HIV-1 variants
with rapid progression, we were unable to determine
whether viruseswere transmitted as homogeneous adapted
founder strains or whether escape mutations quickly
emerge through the robust replicative profile in acute
infection. Nevertheless, the presence of viruses with
complex mutational patterns found only at late stages of
disease [23,26,40] and homogeneous populations of escape
mutants in early infection seem to indicate that
transmission events are the origin of these pathogenic
strains. Thus, rapid progression could originate from
acquisition of HIV-1 from chronically infected untreated
individuals [41]. These source patients increase the
probability of transmission of X4/DM or pathogenic
R5 variants [42], which are fully replicative and adapted to
host HLA through long-term viral replication.
The limitations of the present study include the lack of
transmission pairs to clarify the contribution of founder
viruses to rapid progression. Moreover, ideally, compari-
sons between groups should be made during acute stages,
which might minimize differences at baseline. However,
this would reduce the number of study participants and
thus make it difficult to draw conclusions. Additionally,
availability of biological material was limited owing to the
size and heterogeneity of the samples included in some
sub-analyses.
In conclusion, our findings suggest that rapid progression
results from the acquisition of highly pathogenic strains
already adapted to HLA class I alleles. These strains
avoid the initial control of HIV-1 replication mediated
by adaptive CD8þ T-cell responses, leading to rapid
progression, and might help to explain the increased
virulence of HIV-1 observed over the course of the
epidemic [43]. Therefore, it would be advisable to
develop strategies for early identification of rapid
progressors, specific clinical guidelines, and robustpyright © Lippincott Williams & Wilkins. Unauthoprevention policies in order to provide adequate care
and to prevent the spread of highly pathogenic viral
strains in the population.Acknowledgements
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